In vitro biocompatibility testing of implantable biomaterials

Romanian Biotechnological Letters

Volumn 13, Issue 4, 2008, Pages 3863-3872

  Radu, Albulescu ^a,b   Eleonora, Codorean ^b   Lucian, Albulescu ^b   Georgeta, Caraene ^a   Virginia, Vulturescu ^a   Cristiana, Tanase ^b  

^a NATIONAL INSTITUTE FOR CHEMICAL PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (Romania)

^b National Institute for R and D in Electrical Engineering   (Romania)

Author keywords

Biocompatbility; Cell cultures; Cytokines; Cytotoxicity

Indexed keywords

EID: 77955916820     PISSN: 12245984     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. European Standard: Biological evaluation of medical devices Part 5: Tests for in vitro cytotoxicity 1999 EN ISO 109935: 1999
2. European Standard: Biological evaluation of medical devices Part 1: Evaluation and testing 2004 EN ISO 109931: 2004
3. LIEBSCH HM, SPIELMANN H. Balb/c 3T3 cytotoxicity test. Methods Mol Biol. 1995; 43:177-87
4. LIEBSCH M, SPIELMAN H. Balb/C -3T3 Cytotoxicty assay (Invittox protocol No.46) 2006 European Centre for the Validation of Alternative Methods http://ecvam-dbalm.jrc.ec.europa.eu/
5. SUPINO R. MTT assay (Invittox Protocol No. 17) 1990, European Centre for the Validation of Alternative Methods, http://ecvam-dbalm.jrc.ec.europa.eu/
6. MOSMANN T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983; 65: 55-63.
7. HANSEN MB, NIELSEN SE, BERG K. Reexamination and further development of a precise and rapid dye method for measuring cell growth/cell kill. Journal of immunological methods 1989; 119: 203-210
8. KIRKPATRICK CJ, PETERS K, HERMANNS MI, BITTINGER F, KRUMP-KONVALINKOVA V, FUCHS S, UNGER RE. In vitro methodologies to evaluate biocompatibility: status quo and perspective. ITBM-RBM 2005; 26:192-199
9. RHODES NP. Inflammatory signals in the development of tissue-engineered soft tissue. Biomaterials 2007; 28:5131-36
10. DIMITRIOU R, TSIRIDIS E, GIANNOUDIS PV. Current concepts of molecular aspects of bone healing. Injury 2005; 36:1392-1404
11. NIKOLAOU VS, TSIRIDIS E. Pathways and signalling molecules. Current Orthopaedics 2007; 21(4): 249257
12. LOMAS RJ, GILLAN HL, MATTHEWS JB, INGHAM E, KEARNEY JN. An evaluation of the capacity of differently prepared demineralised bone matrices (DBM) and toxic residuals of ethylene oxide (EtOx) to provoke an inflammatory response in vitro -Biomaterials 2001; 22(9): 913-921
13. SCHMIDT DR, KAO WJ. The interrelated role of fibronectin and interleukin-1 in biomaterial-modulated macrophage function. Biomaterials, 28 (3), p.371-382, 2007
14. LI Y, SCHUTTE RJ, ABU-SHAKRA A, REICHERT WM. Protein array method for assessing in vitro biomaterial-induced cytokine expression. Biomaterials 2005; 26(10): 1081-1085
15. KAPANEN A, ILVESARO J, DANILOV A, RYHANEN J, LEHENKARI P, TUUKKANEN J. Behaviour of Nitinol in osteoblast-like ROS-17 cell cultures Biomaterials 2002; 23(3): 645-650
16. KAPANEN A, KINNUNEN A, RYHANEN J, TUUKKANEN J. TGF-β1 secretion of ROS-17/2.8 cultures on NiTi implant material-Biomaterials 2002; 23(16): 3341-3346.
17. BADYLAK SF. Xenogeneic extracellular matrix as a scaffold for tissue reconstruction. Transplant Immunology 2004; 12(3): 367-377
18. FOURNIER E, PASSIRANI C, MONTERO-MENEI CN, BENOIT JP. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials 2003; 24(19): 3311-333119
19. CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay. 2007; Promega Technical Bulletin TB112 -Promega Corporation Madison, WI 53711-5399 USA